Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients
The aim of this study was to determine the sensitivity, specificity, and predictive values of serum HER-2 for detecting metastatic recurrence in breast cancer patients.
In the period 2004–2009, serum HER-2 was measured in 1,348 patients with breast cancer: 837 during routine controls at the Oncology Department and 511 newly diagnosed. The patients with positive serum HER-2, all the newly diagnosed and 1/5 of the patients with negative serum HER-2 were followed with serum HER-2 measurements every 3–12 months using the ADVIA Centaur assay. Tissue HER-2 status was determined by IHC and FISH. Patients with a single serum HER-2 value above 15 μg/L were considered serum positive. Metastases were diagnosed according to the routine clinical methods using imaging/biopsy.
Of the 862 patients included, 21 had unavailable medical records and were excluded. Patients with unknown tissue status (218), missing blood sample before recurrence (74), or presenting with primary metastatic disease (9) were also excluded. Blood samples before the detection of metastatic recurrence were available in 154 tissue HER-2-positive and in 386 tissue HER-2-negative patients. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-positive patients with values above 15 μg/L were 69 % (95 % CI 53–80 %), 71 % (62–78), 47 % (35–59), and 86 % (77–91), respectively. Combining the cutoff value of 15 μg/L with a delta value of >100 % increase from individual baseline after primary therapy, or increasing the cutoff to 32 μg/L raises the specificity to 96 %, but lowers the sensitivity to 50 and 47 %, respectively. Preoperative serum HER-2 values were accessible in 69 tissue-positive patients, but no significant association was found with later development of metastases. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-negative patients with values above 15 μg/L were 33 % (21–47), 77 % (73–82), 18 % (12–27), and 88 % (84–91), respectively.
Monitoring tissue HER-2-positive breast cancer patients with serum HER-2 has a sufficient sensitivity to detect metastatic recurrence, while its use in monitoring of tissue HER-2-negative patients is unsatisfactory.
KeywordsBreast cancer Metastases Predictive values Sensitivity Serum HER-2 Specificity
Human epidermal growth factor receptor 2
Fluorescence in situ hybridization
Fluorouracil, epirubicin, cyclophosphamide
Computed tomography/ultrasound/magnetic resonance
Human neu unit
- CA 15-3
Cancer antigen 15-3
- Gerhardt W, Keller H (1986) Evaluation of test data from clinical studies. I. Terminology, graphic interpretation, diagnostic strategies, and selection of sample groups. II. Critical review of the concepts of efficiency, receiver operated characteristics (ROC), and likelihood ratios. Scand J Clin Lab Invest Suppl 181:1–74PubMedGoogle Scholar
- Menden H, Mielke S, Marx D, Wuttke W, Kuhn W (1997) Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 17:3075–3077Google Scholar
- Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS, Brandslund I. (2013) Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med, pp1–9, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621. doi: 10.1515/cclm-2012-0488
- Zabrecky JR, Lam T, McKenzie SJ, Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:171Google Scholar